These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15005216)

  • 1. Clinical experience with dofetilide in the treatment of patients with atrial fibrillation.
    Prystowsky EN; Freeland S; Branyas NA; Rardon DP; Fogel RI; Padanilam BJ; Rippy JS
    J Cardiovasc Electrophysiol; 2003 Dec; 14(12 Suppl):S287-90. PubMed ID: 15005216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic Conversion during Dofetilide Treatment for Persistent Atrial Fibrillation.
    Steinberg JS; Shah Y; Szepietowska B
    Pacing Clin Electrophysiol; 2017 Jun; 40(6):667-671. PubMed ID: 28220940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dofetilide in adult patients with atrial arrhythmias and congenital heart disease: A PACES collaborative study.
    El-Assaad I; Al-Kindi SG; Abraham J; Sanatani S; Bradley DJ; Halsey C; Law IH; Balaji S; Shetty I; Aziz PF
    Heart Rhythm; 2016 Oct; 13(10):2034-9. PubMed ID: 27435587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnitude of increase in QTc interval after initiation of dofetilide in patients with persistent atrial fibrillation is associated with increased rates of pharmacological cardioversion and long-term freedom from recurrent atrial fibrillation.
    Huang HD; Waks JW; Steinhaus DA; Zimetbaum P
    Heart Rhythm; 2016 Jul; 13(7):1410-7. PubMed ID: 26921760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
    Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
    J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival.
    Khurshid S; Akerman S; Man JP; Supple G; Dixit S; Epstein AE; Marchlinski FE; Frankel DS
    J Interv Card Electrophysiol; 2015 Mar; 42(2):117-24. PubMed ID: 25620152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
    Singh S; Zoble RG; Yellen L; Brodsky MA; Feld GK; Berk M; Billing CB
    Circulation; 2000 Nov; 102(19):2385-90. PubMed ID: 11067793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide.
    Brumberg G; Gera N; Pray C; Adelstein E; Barrington W; Bazaz R; Mendenhall GS; Nemec J; Voigt A; Wang NC; Schwartzman D; Saba S; Jain SK
    Am J Cardiol; 2013 Aug; 112(4):505-8. PubMed ID: 23706388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes and Characteristics With Dofetilide in Atrial Fibrillation Patients Considered for Implantable Cardioverter-Defibrillator.
    Koene RJ; Menon V; Cantillon DJ; Dresing TJ; Martin DO; Kanj M; Saliba WI; Tarakji KG; Baranowski B; Hussein AA; Tchou PJ; Bhargava M; Callahan TD; Rickard JW; Niebauer MJ; Chung MK; Varma N; Wilkoff BL; Lindsay BD; Wazni OM
    Circ Arrhythm Electrophysiol; 2020 Jul; 13(7):e008168. PubMed ID: 32538135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute conversion of persistent atrial fibrillation during dofetilide initiation.
    Cotiga D; Arshad A; Aziz E; Joshi S; Koneru JN; Steinberg JS
    Pacing Clin Electrophysiol; 2007 Dec; 30(12):1527-30. PubMed ID: 18070309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter.
    Abraham JM; Saliba WI; Vekstein C; Lawrence D; Bhargava M; Bassiouny M; Janiszewski D; Lindsay B; Militello M; Nissen SE; Poe S; Tanaka-Esposito C; Wolski K; Wilkoff BL
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):772-6. PubMed ID: 26063741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation.
    Coleman CI; Sood N; Chawla D; Talati R; Ghatak A; Kluger J;
    Europace; 2009 Jul; 11(7):892-5. PubMed ID: 19351630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrocardiographic markers of repolarization heterogeneity during dofetilide or sotalol initiation for paroxysmal atrial fibrillation.
    Sauer AJ; Kaplan R; Xue J; Dorsey P; Hayes M; Shah SJ; Passman R
    Am J Cardiol; 2014 Jun; 113(12):2030-5. PubMed ID: 24793679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
    Mykytsey A; Bauman JL; Razminia M; Zheutlin T; Wang T; Saleem M; Leal S; Kehoe RF
    J Cardiovasc Pharmacol Ther; 2007 Mar; 12(1):36-43. PubMed ID: 17495256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy.
    Pedersen OD; Bagger H; Keller N; Marchant B; Køber L; Torp-Pedersen C
    Circulation; 2001 Jul; 104(3):292-6. PubMed ID: 11457747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
    Torp-Pedersen C; Brendorp B; Køber L
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2695-704. PubMed ID: 11060831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter.
    Banchs JE; Wolbrette DL; Samii SM; Penny-Peterson ED; Patel PP; Young SK; Gonzalez MD; Naccarelli GV
    J Interv Card Electrophysiol; 2008 Nov; 23(2):111-5. PubMed ID: 18688699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.